Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
Zhenggang Ren
,
Jianming Xu
,
Yuxian Bai
,
Zhenggang Ren
,
Jianming Xu
,
Yuxian Bai
,
Aibing Xu
,
Shundong Cang
,
Chengyou Du
,
Qiu Li
,
Yinying Lu
,
Yajin Chen
,
Yabing Guo
,
Zhendong Chen
,
Baorui Liu
,
Weidong Jia
,
Jian Wu
,
Junye Wang
,
Guoliang Shao
,
Bixiang Zhang
,
Yunfeng Shan
,
Zhiqiang Meng
,
Jianbing Wu
,
Shanzhi Gu
,
Wei Yang
,
Chao Liu
,
Xuetao Shi
,
Zhenyuan Gao
,
Tao Yin
,
Jiuwei Cui
,
Ming Huang
,
Bao-Cai Xing
,
Yilei Mao
,
Gao‐Jun Teng
,
Yanru Qin
,
Jinhai Wang
,
Feng Xia
,
Guowen Yin
,
Yong Yang
,
Mingxia Chen
,
Yan Wang
,
Hui Zhou
,
Jia Fan
2021
The Lancet Oncology
984 citations